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Lipoprotein(a) [Lp(a)] is a lipoprotein moiety with similar 
lipid composition to low-density lipoprotein (LDL). It is com-
posed of apolipoprotein B100 (ApoB100) and apolipoprotein(a) 
(apo(a)) bound by a single disulphide bridge[1,2]. Apo(a) is a 
large hydrophilic glycoprotein, which shares 80-90% homology 
with plasminogen. Homology was confirmed by sequencing 
of cloned human apo(a) cDNA[3]. The role of Lp(a) in health 
and disease is not yet fully understood. It has been suggested 
that Lp(a) has prothrombotic properties. Lp(a) competes with 
plasminogen for binding to endothelial and mononuclear 
cells as well as to platelets, thereby reducing the conversion 
of plasminogen to plasmin and inhibiting fibrinolysis[4]. Fur-
thermore, elevated Lp(a) has been associated with increased 
risk for the development of cardiovascular (CV) and cerebro-
vascular atherosclerotic disease[5,6]. Interestingly, raised levels 
of Lp(a) have been observed in women with polycystic ovary 
syndrome (PCOS) and patients suffering from venous throm-
boembolism[5]. In 1998, Igarashi et al. suggested that serum 
Lp(a) concentration was a significant independent positive 
predictor for left atrial thrombus in patients with chronic atrial 
fibrillation (AF)[3]. 
AF is a major cause of morbidity and hospitalization. 
Moreover, AF is an important risk factor for thromboembolic 
complications and cerebrovascular disease[7]. Some available 
data have demonstrated that AF is associated with ischemic 
heart disease (IHD), arterial hypertension, heart failure (HF), 
obesity and metabolic syndrome (MetS)[8]. In recent years, 
Lp(a) has emerged as an important CV risk factor[4]. In several 
studies and meta-analysis, Lp(a) has been associated with an 
increased incidence of coronary heart disease (CHD). Igarashi 
et al. found that patients with AF and left atrial thrombus had 
elevated levels of Lp(a)[3]. In vitro and in vivo studies support 
the hypothesis that Lp(a) has thrombogenic effects and may 
promote thrombus formation in the left atrium in patients with 
chronic AF, by inhibiting the fibrinolytic system[3]. However, 
Diaz-Peromingo et al. in 2006 found no statistically significant 
differences between the groups of patients with or without 
AF, suggesting that Lp(a) levels are not clearly associated 
with AF[5]. This might be partly explained by the hypothesis 
that Apo(a) (which is similar in structure to plasminogen) 
interferes with fibrinolytic system[8]. Aronis et al.[9] found no 
association between circulating levels of Lp(a) at baseline and 
AF incidence. These results were similar among whites and 
blacks and men and women[9]. In 2011 Naji and Sabovic also 
did not find any positive correlation between Lp(a) and AF[8]. 
Their results were similar to data obtained by Diaz-Peromingo 
et al., who did not find any relationship between Lp(a) levels 
and AF[5]. Naji and Sabovic compared results between a group 
of patients with AF and a control group with sinus rhythm. 
Each group was comprised of 101 patients. In the AF group, 
they found a higher total cholesterol/high density lipoprotein 
(HDL) ratio, but there were no different between the groups in 
terms of Lp(a) levels. Their results were probably influenced 
by ethnic characteristics[5]. Aronis et al. tried to minimalize 
the risk of false negative/positive results caused by ethnic 
characteristics by recruiting 9,908 participants (43.9% men, 
21.6% black) and their study design enabled investigation 
of statistical interaction by race and sex. Furthermore, Lp(a) 
levels were measured with a well-validated assay that is ro-
bust to different Apo(a) isoform sizes[9]. On the other hand, 
Wen-Jia et al. [2016], found a significant association between 
Lp(a) levels and AF.  These authors demonstrated association 
of elevated Lp(a) levels with increasing risk of new-onset AF 
currency (p<0.05, 95%, CI (1.005-7.22)). They followed 534 
patients with chronic heart failure without AF from their 
admission until a new occurrence of AF[10]. The relationship 
between Lp(a) and AF might arise from a connection between 
Lp(a) and inflammation and the fact that its similarity with 
plasminogen results in interference with the fibrinolytic sys-
tem. Moreover, differences between the results reported by 
Wen-Jia and those reported by Naji and by Sabovic might be 
due to different baseline characteristics of the enrolled patients 
such as cardiac function, lipid levels and prevalence of coro-
nary heart disease[8,10]. Additionally, the study conducted by 
Wen-Jia et al.[2], was carried on the Chinese population, Aronis 
et al.[9], included white and black participants, whereas the 
Diaz-Peromingo study population was comprised of white 
European patients[5]. Ethnic differences in CV risk factors have 
been previously described. Higher levels of Lp(a) have been 
reported in Hispanics and African Americans than in white 
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Americans, Europeans or Asians. Blacks have approximately 
3-fold higher Lp(a) levels compared with whites, and women 
have higher Lp(a) levels by 15% - 20% compared with men. 
Despite higher Lp(a) levels, Blacks and women have a lower 
incidence of AF, and little is known about whether race or 
sex modify Lp(a)-related risk[10,11]. It has been suggested that 
genetic factors account for much of the variation in serum 
Lp(a) of different populations. The prevalence of AF also 
varies greatly between ethnic groups. Whites have a greater 
frequently of AF than Black African, Black Caribbean or 
Asian populations[12,13]. Therefore, population studies which 
have included white European patients may report higher 
prevalence of AF and lower levels of Lp(a). These special 
characteristics of populations may in part describe the lack 
of association between variables in several studies. Therefore 
further studies are still needed to elucidate the role of Lp(a) 
in AF in different racial groups.
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